Orosomucoid 1 Participates in Alveolar Hypercoagulation and Fibrinolytic Inhibition Involving NF-κB Signaling Pathway in LPS-Induced ARDS.
Summary
In LPS-induced ARDS, ORM1 is upregulated in lung tissue and BALF and drives TF and PAI-1 expression via NF-κB in AEC II cells. Clinical BALF from ARDS patients shows elevated ORM1 that correlates with TF/PAI-1, positioning ORM1/NF-κB as a mechanistic driver and potential therapeutic target for alveolar hypercoagulation and fibrinolytic shutdown.
Key Findings
- ORM1 is upregulated in lung tissue and BALF in LPS-induced ARDS and correlates with TF, PAI-1, and type III collagen.
- In vitro, ORM1 increases TF and PAI-1 expression in LPS-stimulated AEC II cells via the NF-κB pathway.
- ARDS patient BALF shows elevated ORM1 that positively correlates with TF and PAI-1 levels.
Clinical Implications
Measuring BALF ORM1 may aid risk stratification for alveolar coagulopathy, and pharmacologic modulation of ORM1/NF-κB could mitigate refractory hypoxemia by restoring local fibrinolysis.
Why It Matters
This work links a specific acute-phase protein (ORM1) to the coagulation–fibrinolysis imbalance in ARDS across animal, cellular, and clinical specimens, revealing a tractable NF-κB–dependent mechanism.
Limitations
- LPS-induced ARDS may not capture the full heterogeneity of human ARDS etiologies.
- Clinical cohort size and longitudinal dynamics of ORM1 were not reported, limiting prognostic inference.
Future Directions
Validate ORM1 as a prognostic biomarker in larger prospective ARDS cohorts and test whether targeting ORM1/NF-κB attenuates alveolar coagulopathy and improves clinical outcomes.
Study Information
- Study Type
- Case-control
- Research Domain
- Pathophysiology
- Evidence Level
- III - Preclinical in vivo and in vitro experiments with clinical BALF correlations; non-randomized comparative analyses.
- Study Design
- OTHER